So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...
Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...
In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which ...
We recently published 13 Best ADR Stocks to Invest In. Sanofi (NASDAQ:SNY) is one of the best ADR stocks. Sanofi (NASDAQ:SNY) ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, Canaccord Genuity analyst John Newman reaffirmed a Buy rating on ...
EoE diagnosis is on the rise, and not all treatments have been successful. A Utah physician researcher explores how diet and ...
Regeneron Pharmaceuticals, Inc. ( REGN) Evercore 8th Annual Healthcare Conference December 2, 2025 1:20 PM EST ...
ADRs, or American Depository Receipts, are the US-listed securities of foreign firms that allow investors in America to buy ...
Clinical Trials Arena on MSN
Mabwell’s mAb leads to 40% reduction in severe COPD exacerbations
A Chinese Phase IIb trial of the mAb has already started, with Mabwell also hoping to initiate a Phase IIa trial in the US.
A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...
With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...
Kymera drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial
Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback